Lizzy Smyth, Consultant Medical Oncologist in upper GI oncology at Oxford University NHS Foundation Trust, shared a post on X:
“Radiotherapy does not add to mFOLFIRINOX in borderline resectable Pancreatic Cancer – results for PRODIGE-44.
Good news for patients with PDAC – mFOLFIRINOX had outcomes (mOS 32.8m, 47.9m OS if resected).
Results confirm ESMO guidelines recommendations.”
Sunnie Kim, GI Medical Oncologist at University of Colorado Cancer Center, shared this post, adding:
“Pancreatic cancer is a systemic disease unless proven otherwise!”
Sources: Lizzy Smyth/X and Sunnie Kim/X